Characteristics of patients admitted with COVID-19 by obesity class
| Characteristic | Underweight (BMI <18.5 kg/m2) n=40 | Normal weight (18.5–24.9 kg/m2) n=405 | Overweight (25.0–29.9 kg/m2) n=455 | Obese (30.0–39.9 kg/m2) n=366 | Morbidly obese (>40.0 kg/m2) n=71 |
| Age (Years) | 78 (56, 87) | 71 (59, 82) | 65 (54, 74) | 62 (50, 70) | 53 (41, 62) |
| Female | 16 (40%) | 152 (38%) | 155 (34%) | 152 (41%) | 41 (58%) |
| Race | |||||
| Black | 7 (18%) | 42 (10%) | 54 (12%) | 60 (16%) | 19 (27%) |
| White | 16 (40%) | 157 (39%) | 177 (39%) | 139 (38%) | 26 (37%) |
| Asian | 11 (28%) | 67 (17%) | 59 (13%) | 18 (4.9%) | 4 (5.6%) |
| Other | 3 (7.5%) | 93 (23%) | 102 (22%) | 89 (24%) | 12 (17%) |
| Not specified | 3 (7.5%) | 46 (11%) | 63 (14%) | 60 (16%) | 10 (14%) |
| Outside transfer | 4 (10%) | 51 (13%) | 64 (14%) | 39 (11%) | 7 (9.9%) |
| Smoking status | |||||
| Active smoker | 2 (5.0%) | 11 (2.7%) | 18 (4.0%) | 14 (3.8%) | 2 (2.8%) |
| Former smoker | 9 (22%) | 91 (22%) | 121 (27%) | 77 (21%) | 21 (30%) |
| No | 29 (72%) | 303 (75%) | 315 (69%) | 277 (75%) | 48 (68%) |
| Comorbidities | |||||
| Diabetes mellitus | 13 (32%) | 108 (27%) | 151 (33%) | 118 (32%) | 27 (38%) |
| Hypertension | 25 (62%) | 218 (54%) | 254 (56%) | 218 (60%) | 44 (62%) |
| COPD | 2 (5.0%) | 25 (6.2%) | 21 (4.6%) | 13 (3.6%) | 9 (13%) |
| Asthma | 2 (5.0%) | 29 (7.2%) | 26 (5.7%) | 48 (13%) | 19 (27%) |
| ESRD | 5 (12%) | 34 (8.4%) | 26 (5.7%) | 17 (4.6%) | 3 (4.2%) |
| CAD | 10 (25%) | 66 (16%) | 81 (18%) | 52 (14%) | 13 (18%) |
| Heart failure | 8 (20%) | 45 (11%) | 31 (6.8%) | 24 (6.6%) | 8 (11%) |
| Active cancer | 5 (12%) | 49 (12%) | 28 (6.2%) | 22 (6.0%) | 3 (4.2%) |
| CVA | 5 (12%) | 49 (12%) | 30 (6.6%) | 16 (4.4%) | 4 (5.6%) |
| Cirrhosis | 0 (0%) | 8 (2.0%) | 2 (0.4%) | 5 (1.4%) | 0 (0%) |
| History of transplant | 1 (2.5%) | 20 (4.9%) | 17 (3.7%) | 16 (4.4%) | 3 (4.2%) |
| Immunocompromised | 1 (2.5%) | 24 (5.9%) | 11 (2.4%) | 9 (2.4%) | 1 (1.4%) |
| In-Hospital events | |||||
| Myocardial infarction | 3 (7.5%) | 26 (6.4%) | 21 (4.6%) | 21 (5.7%) | 4 (5.6%) |
| Arrythmia | 0 (0%) | 50 (12%) | 55 (12%) | 45 (12%) | 8 (11%) |
| VTE | 1 (2.5%) | 42 (10%) | 44 (9.7%) | 46 (13%) | 6 (8.5%) |
| Acute kidney injury | 6 (15%) | 74 (18%) | 80 (18%) | 72 (20%) | 11 (15%) |
| Renal replacement | 3 (7.5%) | 38 (9.4%) | 37 (8.1%) | 45 (12%) | 7 (9.9%) |
| Home medications | |||||
| NSAID | 12 (30%) | 118 (29%) | 127 (28%) | 102 (28%) | 21 (30%) |
| ACE inhibitor | 8 (20%) | 114 (28%) | 130 (29%) | 110 (30%) | 26 (37%) |
| Statins | 13 (32%) | 153 (38%) | 171 (38%) | 138 (38%) | 23 (32%) |
| Inpatient therapies | |||||
| Antibiotics | 24 (60%) | 225 (56%) | 252 (56%) | 208 (57%) | 35 (49%) |
| Steroids | 8 (20%) | 115 (28%) | 137 (30%) | 124 (34%) | 26 (37%) |
| Hydroxychloroquine | 15 (38%) | 238 (59%) | 310 (68%) | 260 (71%) | 46 (65%) |
| Tocilizumab | 0 (0%) | 19 (4.7%) | 26 (5.7%) | 23 (6.3%) | 3 (4.2%) |
| Vasopressors | 6 (15%) | 102 (25%) | 140 (31%) | 134 (37%) | 22 (31%) |
| Remdesivir | 1 (2.5%) | 23 (5.7%) | 38 (8.4%) | 31 (8.5%) | 10 (14%) |
| IVIG | 1 (2.5%) | 3 (0.7%) | 5 (1.1%) | 7 (1.9%) | 0 (0%) |
| Outcomes | |||||
| Discharge to home | 15 (38%) | 216 (53%) | 275 (60%) | 217 (59%) | 53 (75%) |
| Length of stay | 5.9 (3.1, 13.3) | 8.0 (3.8, 18.6) | 9.0 (4.2, 22.2) | 8.6 (4.0, 24.9) | 7.3 (3.9, 16.6) |
| Length of stay (survivors only) | 6.1 (4.2, 14.8) | 7.7 (3.8, 16.6) | 8.5 (3.9, 22.0) | 8.5 (4.0, 26.8) | 7.0 (3.8, 16.0) |
| Death | 15 (38%) | 98 (24%) | 62 (14%) | 56 (15%) | 10 (14%) |
Baseline values are presented as median (25–75th percentile) for continuous variables and N (%) for categorical variables.
ACE, angiotensin converting enzyme; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRD, end-stage renal disease; IVIG, intravenous immunoglobulin; NSAID, non steroidal anti-inflammatory drug; VTE, venous thromboembolic event.